Methylenetetrahydrofolate reductase gene polymorphism: Relation to blood pressure and cerebrovascular disease

American Journal of Hypertension

Volumn 11, Issue 8 I, 1998, Pages 1019-1023

  Nakata, Yukiko ^a   Katsuya, Tomohiro ^a   Takami, Seiju ^a   Sato, Noriyuki ^a   Fu, Yuxiao ^a   Ishikawa, Kazuhiko ^a   Takiuchi, Shin ^a   Rakugi, Hiromi ^a   Miki, Tetsuro ^a   Higaki, Jitsuo ^a   Ogihara, Toshio ^a,b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Genetics; Hyperhomocysteinemia; Hypertension; Thrombosis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HOMOCYSTEINE;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; JAPAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR; THROMBOGENESIS;

CEREBROVASCULAR DISORDERS; FOLIC ACID; HOMOCYSTEINE; HUMANS; HYPERTENSION; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MUTATION; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 0031847010     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(98)00046-6     Document Type: Article

References (20)

1. Clarke R, Daly L, Robinson K, et al: Hyperhomocysteinemia: an independent risk factor for vascular diseases. N Engl J Med 1991;324:1149-1155.
2. Gmurphy-Chutorian D, Alderman EL: The case that hyperhomocysteinemia is a risk for coronary artery disease. Am J Cardiol 1994;73:705-707.
3. Arnrtson E, Refsum H, Bonaa KH, et al: Serum total homocysteine and coronary heart diseases. Int J Epidemiol 1995;24:704-709.
4. Robinson K, Mayer EL, Millert DP, et al: Hyperhomocysteinemia and low pyridoxalphosphate: common and independent reversible risk factors for coronary artery disease. Circulation 1995;92:2825-2830.
5. Stampfer MJ, Malinow MR, Willett WC, et al: A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992;24: 704-709.
6. Brattstrom L, Lindgren A, Israelsson B, et al: Hyperhomocysteinemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors. Eur J Clin Invest 1992;22:214-221.
7. Verhoef P, Hennekens CH, Mailnow MR, et al: A prospective study of plasma homocysteine and risk of ischemic stroke. Stroke 1994;25:1924-1930.
8. den Heijer M, Koster T, Blom HJ, et al: Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996;334:759-762.
9. den Heijer M, Blom HJ, Gerrits WBJ, et al: Is hyperhomocysteinemia a risk factor for recurrent venous thrombosis? Lancet 1995;345:882-885.
10. Boushey CJ, Beresford SA, Omenn GS, et al: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-1057.
11. Blom HJ, VandeMolen E: Pathobiochemical implications of hyperhomocysteinemia. Fibrinolysis 1991;8(suppl 2): 86-87.
12. Frosst P, Blom HJ, Milos R, et al: A candidate genetic risk factor for vascular disease: a common mutation in methylene tetrahydrofolate reductase. Nat Genet 1995; 10:111-113.
13. Special report from the National Institute of Neurological Disorders and Stroke: Classification of cerebrovascular disease III. Stroke 1990;21:637-676.
14. Tsai JC, Perrella MA, Yoshizumi M, et al: Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91:6369-6373.
15. Tsai JC, Wang H, Perrella MA, et al: Induction of cyclin A gene expression by homocysteine in vascular endothelial cell activator. J Clin Invest 1986;97:146-153.
16. Rodger GM, Kante WH: Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986;97:1370-1376.
17. Lentz SR, Sadler JE: Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991;88:1906-1916.
18. Rodger GM, Conn MT: Homocysteine, an atherogenic stimulus reduces protein C activation by arterial and venous endothelial cells. Blood 1990;75:895-901.
19. Hajjar KA: Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993;91:2873-2879.
20. Wilken DEL, Wang XL, Sim AS, et al: Distribution in healthy and coronary populations of the methylenetetrahydrofolate reductase (MTHFR) C677 T mutation. Arterioscler Thromb Vase Biol 1996;16:878-882.